As a politician help us close the gap
Raise awareness of symptoms
Despite accounting for 51.1% of common cancer deaths the less survivable cancers still suffer from low awareness amongst the public and health practitioners. Delays in diagnosis have a detrimental effect on survival of these rapidly-advancing diseases, which are currently difficult or impossible to treat at later stages.
- Persuade healthcare providers in your constituency to raise awareness of symptoms.
Speed up paths to treatment
If you have a less survivable cancer, you are twice as likely not to be diagnosed until you are in enough pain to go to A&E, compared to someone with a more survivable cancer. Late diagnosis and slow progress to treatment can severely limit treatment options for patients, who then face poorer survival prospects at 12, 24, and 36 months onwards.
Relationship between diagnosis through emergency routes and length of survival. Data combined from the National Cancer Registration and Analysis Service (NCRAS), England. Simon, A. E. et al. Knowledge of lung cancer symptoms and risk factors in the U.K.: development of a measure and results from a population-based survey. Thorax 67, 426-432, doi:10.1136/thoraxjnl-2011-200898 (2012).
To follow the footsteps of more survivable cancers, trials of screening higher-risk individuals and fast-tracking patients with relevant symptoms should take place.
- Ask healthcare providers in your constituency about what they are doing to learn from others and share best practice.
Remove barriers to treatments and trials
The investment in innovation needed to increase survival will only occur if funders feel that their pounds will have impact. Evidence shows there are fewer approved trials for less survivable cancers.
Number of clinical trials by cancer type that currently recruit patients in UK. Horizontal dashed lines demonstrate the average number of clinical trials between the more survivable cancers (upper line) and the less survivable cancers (lower line). Taken from CRUK website, ‘Find a clinical trial’,
Budgeting barriers need to be removed that make treatments such as specialised neuro-rehab available only to a minority. Technology Appraisals need to value relative survival gains as well as absolute, and appreciate the challenges of running trials for diseases with high short-term mortality rates. Only then will life-extending treatments be made available to more patients in need.
- Ask the responsible bodies in your country to remove barriers to treatments.
Share data and set Government-backed survival targets for each cancer
For example, NHS England’s first edition Cancer Dashboard currently only offers data for four cancers, and its overall cancer survival ambition is not broken down on a per-cancer basis. Making data available will be critical if we are to track success in improving outcomes for the less survivable cancers.
- Call on your Government to set targets and share data for each of the less survivable cancers.
Increase investment in research and improve infrastructure
It is no wonder that cancers with better research funding and infrastructure, such as researcher expertise and biobanking, have seen greater innovations in care and improvements in survival.
Between 2002 and 2014, the less survivable cancers received just 16.6% of research funding of common cancers and became responsible for 51.1% of common cancer deaths in the UK in 2014. Greater research will be critical to increasing survival.
Total research funding between 2002 and 2014 for more survivable cancers was 5 times more than it was for less survivable cancers.
These figures were compiled from data received by request privately from NCRI.
- Call on your Government to set survival targets and share data for each of the less survivable cancers.
HELP US CLOSE THE GAP
We need to take action on less survivable cancers now
THE TASKFORCE IS MADE UP
OF THE FOLLOWING CHARITIES